{
  "id": 1769615071608,
  "seqId": 136,
  "title": "DIABETIC EYE DISEASE: ASSESSMENT & MANAGEMENT",
  "summary": "A comprehensive clinical framework for the assessment, grading, and treatment of diabetic eye disease. This guide integrates risk factor evaluation, the Airlie House/ETDRS classification systems, and specific management protocols for retinopathy and maculopathy.",
  "date": "2026-01-28T15:44:31.608Z",
  "data": {
    "title": "DIABETIC EYE DISEASE: ASSESSMENT & MANAGEMENT",
    "summary": "A comprehensive clinical framework for the assessment, grading, and treatment of diabetic eye disease. This guide integrates risk factor evaluation, the Airlie House/ETDRS classification systems, and specific management protocols for retinopathy and maculopathy.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='40' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><circle cx='50' cy='50' r='15' fill='hsl(215, 90%, 45%)' opacity='0.3'/><path d='M30 50 L70 50 M50 30 L50 70' stroke='hsl(215, 90%, 45%)' stroke-width='1'/><circle cx='65' cy='40' r='2' fill='red'/><circle cx='35' cy='60' r='1.5' fill='red'/><circle cx='55' cy='55' r='3' fill='orange' opacity='0.6'/><path d='M20 50 Q 50 10 80 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='1' stroke-dasharray='2,2'/></svg>",
    "sections": [
      {
        "title": "Primary Ophthalmic Aims",
        "icon": "target",
        "type": "process",
        "layout": "full_width",
        "color_theme": "blue",
        "content": [
          "1. Assess risk factors for eye disease (and, to a lesser extent, other systemic complications)",
          "2. Ensure modifiable risk factors are treated",
          "3. Detect and grade eye disease",
          "4. Institute ophthalmic treatment where necessary"
        ]
      },
      {
        "title": "Table 13.4: Patient History (History & Social)",
        "icon": "history_edu",
        "type": "table",
        "layout": "half_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Category",
            "Assessment Details"
          ],
          "rows": [
            [
              "Visual symptoms",
              "Asymptomatic; dVA, distortion, floaters"
            ],
            [
              "POH (Past Ocular History)",
              "Previous diabetic eye complications; laser treatment; surgery; concurrent eye disease"
            ],
            [
              "PMH (Past Medical History)",
              "Diabetes: age of diagnosis, type and duration, ‘who looks after your diabetes?’, ‘what is your long-range diabetes test result/HbA1c?’; hypertension: ‘how often is it checked?’, hypercholesterolaemia, smoking; pregnancy; IHD, cerebrovascular disease, peripheral vascular disease, nephropathy, neuropathy"
            ],
            [
              "SH (Social History)",
              "Driver; occupation"
            ]
          ]
        }
      },
      {
        "title": "Table 13.4: Drug & Allergy Assessment",
        "icon": "medication",
        "type": "table",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "headers": [
            "Category",
            "Details"
          ],
          "rows": [
            [
              "Dx (Drugs)",
              "Treatment for diabetes (diet, oral hypoglycaemics, insulin types, and frequency), hypertension, hypercholesterolaemia; aspirin/antiplatelet agents; warfarin"
            ],
            [
              "Ax (Allergies)",
              "Allergies or relevant drug contraindications"
            ]
          ]
        }
      },
      {
        "title": "CRITICAL DRUG INTERACTION",
        "icon": "warning",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Pioglitazone: Ask specifically about this medication due to its association with macular oedema."
        ]
      },
      {
        "title": "Table 13.4: Clinical Examination Checklist",
        "icon": "visibility",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Structure",
            "Features to Assess"
          ],
          "rows": [
            [
              "VA",
              "Best corrected / pinhole / near"
            ],
            [
              "Cornea",
              "Tear film"
            ],
            [
              "Iris",
              "Rubeosis"
            ],
            [
              "Lens",
              "Cataract"
            ],
            [
              "Tonometry",
              "Intraocular Pressure (IOP)"
            ],
            [
              "Vitreous",
              "Haemorrhage, asteroid hyalosis"
            ],
            [
              "Fundus",
              "Retinopathy (microaneurysms, haemorrhages, exudates, IRMAs, venous beading, venous loops, neovascularization), maculopathy (fluid, exudates, retinal thickening), TRD/RRD, arterial/venous occlusion, ocular ischaemia"
            ],
            [
              "Disc",
              "New vessels, papillitis, AION"
            ]
          ]
        }
      },
      {
        "title": "Table 13.5: Definitions in Diabetic Eye Disease",
        "icon": "menu_book",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Grade",
            "Clinical Findings"
          ],
          "rows": [
            [
              "Background (low risk)",
              "Microaneurysms, small haemorrhages, hard exudates, occasional CWS"
            ],
            [
              "Pre-proliferative (high risk)",
              "IRMAs, venous beading/loops, clusters of large blot haemorrhages, multiple CWS"
            ],
            [
              "Proliferative: NVD",
              "New vessels at the disc or within 1DD of the disc"
            ],
            [
              "Proliferative: NVE",
              "New vessels elsewhere in the retina"
            ]
          ]
        }
      },
      {
        "title": "High-Risk Proliferative Criteria",
        "icon": "priority_high",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "NVD > 1/3 disc area",
          "Any NVD with vitreous or preretinal haemorrhage",
          "NVE > 1/2 disc area with vitreous or preretinal haemorrhage"
        ]
      },
      {
        "title": "Classification Equivalency",
        "icon": "compare_arrows",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "blue",
        "content": "Effectively, background retinopathy corresponds to mild NPDR, whereas pre-proliferative retinopathy would include the range from moderate to very severe non-proliferative retinopathy. The international (American Academy of Ophthalmology (AAO)) classification has similarities to a simplified form of the Airlie House criteria."
      },
      {
        "title": "Maculopathy Categories",
        "icon": "hub",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "center": "Maculopathy Types",
          "branches": [
            "Focal: Well-circumscribed leakage with oedema and exudate rings (often surrounding microaneurysm)",
            "Diffuse: Generalized leakage with oedema",
            "Ischaemic: dVA with relatively normal appearance; confirmed by macular ischaemia on FFA",
            "Mixed: Combination (e.g., diffuse and ischaemic)"
          ]
        }
      },
      {
        "title": "Clinically Significant Macular Oedema (CSMO)",
        "icon": "biotech",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Retinal thickening at or within 500 microns of the centre of the macula",
          "Hard exudates at or within 500 microns of the centre of the macula if associated with adjacent retinal thickening",
          "Retinal thickening of >1 disc area, any part of which is within 1DD of the centre of the macula",
          "Centre-involving DMO: Thickening involving the foveal centre"
        ]
      },
      {
        "title": "Airlie House Classification (ETDRS NPDR)",
        "icon": "format_list_bulleted",
        "type": "table",
        "layout": "half_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "NPDR Category",
            "Features"
          ],
          "rows": [
            [
              "Mild NPDR",
              "At least one microaneurysm"
            ],
            [
              "Moderate NPDR",
              "Severe retinal haemorrhages in 1 quadrant; OR CWS, venous beading, or IRMA definitely present"
            ],
            [
              "Severe NPDR",
              "Severe retinal haemorrhages in 4 quadrants; OR venous beading in 2 quadrants; OR extensive IRMA in 1 quadrant"
            ],
            [
              "Very Severe NPDR",
              "Any two features of severe NPDR"
            ]
          ]
        }
      },
      {
        "title": "Table 13.6: Retinopathy Management Protocol",
        "icon": "settings_suggest",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Condition",
            "Action / Management"
          ],
          "rows": [
            [
              "None / background",
              "Discharge to community screening for annual review. If significant systemic disease, consider HES review at 9–12mo"
            ],
            [
              "Pre-proliferative",
              "Observe 4- to 6-monthly. Consider early PRP in select cases (e.g., only eye or prior to cataract surgery)"
            ],
            [
              "Proliferative (active)",
              "PRP (1–2 sessions). Wherever possible, occur on same day or within 2wk. Evolving role for anti-VEGF"
            ],
            [
              "Proliferative (regressed)",
              "Observe 4- to 6-monthly. Signs of d neovascularization: vessel regression/fibrosis, resolved haemorrhage, decreased vessel dilatation/tortuosity"
            ],
            [
              "Proliferative + DMO",
              "High-risk: Combined macular laser + PRP (3 sessions). Low-risk: Macular laser first, then PRP follow-up. Anti-VEGF particularly useful"
            ]
          ]
        }
      },
      {
        "title": "Table 13.6: Maculopathy Management Protocol",
        "icon": "eye_tracking",
        "type": "table",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "headers": [
            "Maculopathy Type",
            "Action / Management"
          ],
          "rows": [
            [
              "Focal leakage",
              "Focal laser photocoagulation; review at 3–4mo"
            ],
            [
              "Diffuse leakage",
              "Grid laser photocoagulation; review at 3–4mo. Anti-VEGF now more common for diffuse centre-involving"
            ],
            [
              "Centre-involving oedema",
              "Anti-VEGF (Ranibizumab/Aflibercept) if thickness >400 microns. Dexamethasone implant for pseudophakic eyes if anti-VEGF fails/unsuitable"
            ],
            [
              "Ischaemic",
              "FFA or OCTA to confirm. Observation if significant ischaemia or no response to laser/anti-VEGF"
            ],
            [
              "Persistent",
              "Consider intravitreal fluocinolone (Iluvien) in pseudophakic eyes; consider vitrectomy for VMT"
            ]
          ]
        }
      },
      {
        "title": "Specific Anti-VEGF Regimens",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Ranibizumab: Monthly until VA stable on 3 consecutive visits",
          "Aflibercept: Monthly for 5 months, then every 2 months (extend intervals after Year 1 if appropriate)",
          "Dexamethasone Implant: Repeatable at 4 months (Caution: risk of pressure rise)",
          "Anti-VEGF is approved for centre-involving DMO if thickness >400 microns"
        ]
      },
      {
        "title": "Laser Parameters",
        "icon": "bolt",
        "type": "remember",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": {
          "mnemonic": "LASER SPECS",
          "explanation": "PRP: 1–2 sessions, ≥1,000 burns, 200–500 microns, 0.1s (or 20–30ms for newer lasers). Focal: 50–100 microns, 0.08–0.1s (or 10–20ms for newer lasers)."
        }
      },
      {
        "title": "Special Case: Young Type 1 Patients",
        "icon": "child_care",
        "type": "red_flag",
        "layout": "half_width",
        "color_theme": "red",
        "content": [
          "In young patients with type 1 diabetes, PRP should be delivered over 3–4 sessions.",
          "Reason: Risk of increased macular oedema post-PRP if excess burns are applied in a single session."
        ]
      },
      {
        "title": "Table 13.6: Complications Management",
        "icon": "emergency",
        "type": "table",
        "layout": "full_width",
        "color_theme": "red",
        "content": {
          "headers": [
            "Condition",
            "Specific Management"
          ],
          "rows": [
            [
              "Rubeosis + clear media",
              "Urgent PRP ± anti-VEGF therapies"
            ],
            [
              "Rubeosis + vitreous haemorrhage",
              "Vitrectomy + endolaser"
            ],
            [
              "Rubeotic glaucoma",
              "Urgent PRP/anti-VEGF; dIOP with topical meds, cyclodiode, augmented trabeculectomy, or tubes"
            ],
            [
              "Vit Hge: No view of fundus",
              "US to ensure retina flat + review 2- to 4-weekly until adequate view"
            ],
            [
              "Vit Hge: Adequate view",
              "Ensure retina flat + PRP"
            ],
            [
              "Persistent Vit Hge",
              "Vitrectomy + endolaser + anti-VEGF therapies"
            ]
          ]
        }
      },
      {
        "title": "Guidelines & References",
        "icon": "link",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "For further detail and equivalency of classification systems, refer to the Royal College of Ophthalmologists Diabetic Retinopathy guidelines 2012 available at http://www.rcophth.ac.uk."
      }
    ],
    "chapterId": "uncategorized"
  },
  "chapterId": "medical_retina",
  "_newlyImported": 1769615071608,
  "communityId": "sub_1769614749293_qaiwoph65ezaxy",
  "communityAuthor": "hh",
  "communityDate": "2026-01-28T15:39:09.293Z",
  "_serverSynced": true
}